[ad_1] A 400% price hike on a decades-old drug is a risky move in a post-Martin Shkreli world. But Nirmal Mulye, founder of Nostrum Pharmaceuticals, said he had to raise prices or …
Read More »The CEO of Nostrum says that he was not defending Shkreli, he was condemning the FDA
